HKI-357 is an irreversible dual inhibitor targeting EGFR and ERBB2 with IC50 values of 34 nM and 33 nM, respectively. It effectively blocks EGFR autophosphorylation at Y1068 and downstream AKT and MAPK signaling. This compound is a valuable research tool for investigating oncogenic receptor tyrosine kinase pathways in both in vitro and in vivo cancer models.
